A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Rocacetrapib (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 23 Aug 2016 Status changed from recruiting to completed.
- 03 May 2016 New trial record